Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

Summary

The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.

Timeline

Start

2016-12-20

Primary completion

2019-08-31

Completion

2023-04-26

Outcome

Missed primary endpoint

paper although the activity observed was not as high as the study was powered for. PMID 34695377 ↗

Publications

• Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23.

Drugs

Indications